GV-328

PreclinicalSmall molecule

UUniversitat Internacional de Catalunya

GV-328 is one of 5 small molecule programs targeting Acceptability. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AcceptabilityCompleted

AcceptabilityPreclinical

Completed

Competition

Competitive Landscape

6 competitors in Acceptability

#DrugCompanyPhaseTrials

Jadelle

IItalian Network for Tumor Biotherapy Foundation

Phase 3

3 2

Mifeprex

DDanco

Phase 3

2 3

Verazinc

FFakultas Kedokteran Universitas Indonesia

Preclinical

1 4

Nuvaring

UUniversity of Washington

Preclinical

1 5

GV-328

UUniversitat Internacional de Catalunya

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acceptability1 trial

Safety, Galenic Acceptability and Efficacy of GV-328 Lozenges in Children With Oral Aphthosis

Completed·UUniversitat Internacional de Catalunya·N/A·NCT04677062·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GV-328. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GV-328 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GV-328. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universitat Internacional de Catalunya company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversitat Internacional de Catalunya

GV-328

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acceptability1 trial

References

Drug Info

Quick Facts

Related News